Compound 4-methyl-N-3-(4-methyl-1H-pyridine-1-IL) -5-(trifluoromethyl) phenyl-3-(4-pyridine-3-Ilpirimidin-2-IL) amino) aniline (Nilotinib) is used to treat diffusive disorders or other conditions mediated by Quinasa BCR-ABL, C-Kit, DDR1, DDR2 or PDGF-R, orally managing dispersion. Comments more than a month ago

摘要

Method for treating a proliferative disorder or other Pathological conditions mediated by the activity of kinase of bcr abl, c-kit, DDR1,DDR2 or PDGF - R which comprises oral administration of a compound derived from pirimidil - amino benzamide; and kit comprising the compound derived from pirimidil - amino benzamide.